Germinated moss spores are pictured after being exposed to the rigors of space on the outside of the International Space Station, where the survived for nine months. Photo by Chang hyun-Maeng and Maika Kobayashi/Hokkaido University
Nov. 21 (UPI)…
Premier League clubs have voted to overhaul the league’s financial regulations from the start of the 2026-27 season.
The clubs held a shareholders’ meeting in London on Friday to discuss a range of proposed new financial measures, known as top…
Davies, D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discovery. 2, 114–122 (2003).
Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a…
James Patterson believes Marilyn Monroe was probably murdered. “I think that she was treading in very dangerous waters,” he says. “She had these incredible relationships with President Kennedy, and with Robert Kennedy, and with Sinatra,…
At 501 in 22 countries, the numbers of confirmed highly pathogenic avian influenza (HPAI) outbreaks in commercial poultry have surpassed the totals for 2024, which were 451 and 20, respectively. The outbreak figure looks likely to pass the 2023…
Nothing Phone 3 owners, your Android 16 update is here. Owners of other models? Well, you’ll have to wait a bit longer. Regardless, the company’s Nothing OS 4.0 update brings Google’s newest mobile software, along with a bunch of UI tweaks.
In…
Brigid DeCoursey Bondoc – FDA + Healthcare Regulatory and Compliance Partner, Morrison Foerster
Brigid is a food, drug, and medical device lawyer who counsels life sciences companies on a wide range of U.S. Food & Drug Administration pre- and post-market regulatory issues. As the lead of our FDA + Healthcare Regulatory and Compliance Group, Brigid practices across the spectrum of FDA-regulated products, including medical devices, drugs, biologics, cell and gene therapies, food, cosmetics, dietary supplements, tobacco, laboratory-developed tests, in vitro diagnostics, radiation-emitting electronic products, combination products, and products that may not fit neatly into any of these categories. Accordingly, she counsels established and start-up companies in life sciences, healthcare, and consumer products on a wide range of FDA pre- and post-market regulatory issues. Brigid also frequently advises innovative product developers on threshold FDA jurisdictional questions and develops strategies for approval and marketing, while identifying and mitigating regulatory risks.
